SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.
무작위 임상시험
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
54 patients in the experimental arm and 56 in the control arm.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] While results from the global SKYSCRAPER-02 study were not statistically significant, numerical improvements in PFS and OS were seen with tiragolumab plus atezolizumab plus CE versus atezolizumab plus CE in Chinese patients with ES-SCLC. Biomarker analysis identified immune-inflamed signatures that may guide future TIGIT-based strategies.
OpenAlex 토픽 ·
Lung Cancer Research Studies
Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
[INTRODUCTION] Tiragolumab may synergize with other immunotherapies to enhance antitumor immune responses.
- HR 0.65
- 추적기간 26.7 months
APA
Shun Lu, Jian Fang, et al. (2026). SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 103713. https://doi.org/10.1016/j.jtho.2026.103713
MLA
Shun Lu, et al.. "SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China.." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026, pp. 103713.
PMID
41950998 ↗
Abstract 한글 요약
[INTRODUCTION] Tiragolumab may synergize with other immunotherapies to enhance antitumor immune responses. We report efficacy, safety, and biomarker findings from SKYSCRAPER-02C (NCT04665856), comparing tiragolumab plus atezolizumab plus carboplatin/etoposide (CE; experimental arm) with atezolizumab plus CE (control arm) in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) in China.
[METHODS] Patients were randomized (1:1) to tiragolumab 600 mg or placebo, plus atezolizumab 1200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary endpoints were investigator-assessed progression-free survival (PFS) and overall survival (OS) in patients without history/presence of brain metastases at baseline (primary analysis set [PAS]).
[RESULTS] The PAS comprised 54 patients in the experimental arm and 56 in the control arm. Median PFS was 5.6 months (experimental) and 5.4 months (control; unstratified HR = 0.65, 95% CI: 0.43‒0.97; median follow-up 26.7 months); median OS was 18.7 and 13.5 months, respectively (unstratified HR 0.89, 95% CI: 0.56‒1.40). The biomarker-evaluable population comprised 69 patients with immunohistochemistry data and 66 with RNA sequencing (RNAseq) data. RNAseq survival analysis showed that patients with NMF3 (SCLC-I-NE) or NMF4 (SCLC-I-nNE) molecular subtypes, and those with high T-effector and tumor-associated macrophage immune signatures, benefited from tiragolumab plus atezolizumab plus CE treatment. Tiragolumab was well tolerated with no new safety signals.
[CONCLUSIONS] While results from the global SKYSCRAPER-02 study were not statistically significant, numerical improvements in PFS and OS were seen with tiragolumab plus atezolizumab plus CE versus atezolizumab plus CE in Chinese patients with ES-SCLC. Biomarker analysis identified immune-inflamed signatures that may guide future TIGIT-based strategies.
[METHODS] Patients were randomized (1:1) to tiragolumab 600 mg or placebo, plus atezolizumab 1200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary endpoints were investigator-assessed progression-free survival (PFS) and overall survival (OS) in patients without history/presence of brain metastases at baseline (primary analysis set [PAS]).
[RESULTS] The PAS comprised 54 patients in the experimental arm and 56 in the control arm. Median PFS was 5.6 months (experimental) and 5.4 months (control; unstratified HR = 0.65, 95% CI: 0.43‒0.97; median follow-up 26.7 months); median OS was 18.7 and 13.5 months, respectively (unstratified HR 0.89, 95% CI: 0.56‒1.40). The biomarker-evaluable population comprised 69 patients with immunohistochemistry data and 66 with RNA sequencing (RNAseq) data. RNAseq survival analysis showed that patients with NMF3 (SCLC-I-NE) or NMF4 (SCLC-I-nNE) molecular subtypes, and those with high T-effector and tumor-associated macrophage immune signatures, benefited from tiragolumab plus atezolizumab plus CE treatment. Tiragolumab was well tolerated with no new safety signals.
[CONCLUSIONS] While results from the global SKYSCRAPER-02 study were not statistically significant, numerical improvements in PFS and OS were seen with tiragolumab plus atezolizumab plus CE versus atezolizumab plus CE in Chinese patients with ES-SCLC. Biomarker analysis identified immune-inflamed signatures that may guide future TIGIT-based strategies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
- Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.
- Orbicularis Oculi Toxin Injection for Treating Levator Palpebrae Superioris Weakness: Clinical Effect and Safety in a Cohort Study.
- A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
- Complete Remission in BCLC Stage C Hepatocellular Carcinoma Treated with HAIC Combined with PD-1 Inhibitors and Anti-angiogenic Therapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.